Pharmacology for Anaesthesia and Intensive Care

T. E. PECK AND S. A. HILL



FOURTH EDITION

CAMBRIDGE Medicine

Pharmacology for Anaesthesia and Intensive Care

FOURTH EDITION

Pharmacology for Anaesthesia and Intensive Care

FOURTH EDITION

T. E. Peck
Consultant Anaesthetist, Royal Hampshire County Hospital, Winchester;
Honorary Consultant, University Hospital Southampton, UK

S. A. Hill
Consultant Neuroanaesthetist, University Hospital Southampton, UK

CAMBRIDGE
UNIVERSITY PRESS

CAMBRIDGE
UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org
Information on this title: www.cambridge.org/9781107657267

First published 2000
Second edition 2003
Third edition 2008
Fourth edition 2014
6th printing 2018

Printed in the United Kingdom by TJ International Ltd. Padstow Cornwall

A catalogue record for this publication is available from the British Library

Library of Congress Cataloguing in Publication data
Peck, T. E., author.
Pharmacology for anaesthesia and intensive care / T. E. Peck, S. A. Hill. – Fourth edition.
p. ; cm.
Includes bibliographical references and index.
ISBN 978-1-107-65726-7 (hbk.)
I. Hill, S. A. (Sue A.), author. II. Title.
[DNLM: 1. Anesthetics–pharmacology. 2. Cardiovascular Agents–pharmacology. 3. Central Nervous System Agents–pharmacology. 4. Intensive Care. 5. Peripheral Nervous System Agents–pharmacology. QV 81]
RD82.2
615.7'81–dc23
2014011956

ISBN 978-1-107-65726-7 Paperback

CONTENTS

PREFACE

The style of this fourth edition has remained largely unchanged, as it has proved successful in giving easy access to the contents. In order to keep the overall size similar to previous editions we have culled some of the drugs that had provided a historical perspective and reduced the space given to drugs used less commonly. Drugs that had been discontinued or withdrawn, but more recently been reinstated, are now included in order to remain current. A wide range of drugs that did not exist or were in the trial phase of their development are now included and further add to the breadth of this book. Section 1 has been developed further with a chapter for applied pharmacokinetic models as the use of total intravenous anaesthesia becomes more widespread. We trust that this book will continue to provide current and useful information to the wide readership that it has attracted thus far in its evolution.

FOREWORD

The art of anaesthesia includes many different facets deeply rooted in medical behaviour: listening and talking to the patient, evaluating, diagnosing and taking the right decisions.

Drugs are central to patient care in many areas of medical practice and the anaesthetist as well as all healthcare practitioners need to have a clear understanding of therapeutics. However, competence in anaesthetic management during the whole perioperative management of our patients implies good knowledge of pharmacology; it is the bread and butter of our profession.

The dynamic nature of drug development in this field compels a continuous updating of the characteristics of drugs that form such an essential part of our armamentarium.

Pharmacology for Anaesthesia and Intensive Care, edited by T.E. Peck and S.A. Hill, provides a novel-classic approach to pharmacology.

Drawing on the experience of the authors, who are involved in clinical practice, postgraduate training and assessments, not only in the United Kingdom but with a pan-European view, the changes and improvements introduced in this fourth edition make this textbook an appropriate guide not only for trainees at all stages of their training but also for consultants.

Designed as a refresher textbook, this work is suitable as a reference for daily use as well as in preparing for various medical assessments and examinations.

Its content is fitted to anaesthesia training programmes in pharmacology in many countries. It covers the pharmacology requirements of the new syllabus in anaesthesia and intensive care produced by the European Board of Anaesthesiology of the UEMS (Union of European Medical Specialties) as well that of the Royal College of Anaesthetists.

As for the previous editions, this textbook is part of the recommended bibliography for examination preparation for the European Diploma in Anaesthesiology and Intensive Care (EDAIC).

I know that readers will find this book to be a valuable resource for both examination preparation and clinical use as a practical guide to pharmacology for anaesthesia and intensive care.

Zeev Goldik MD MPH

Chairman, Examinations Committee – European Diploma in Anaesthesiology and Intensive Care

President Elect, European Society of Anaesthesiology

Head of Post Anaesthesia Care Unit and Consultant Anaesthetist, Lady Davis Carmel Medical Centre, Haifa, Israel

SECTION I **Basic principles**

1 Drug passage across the cell membrane

Many drugs need to pass through one or more cell membranes to reach their site of action. A common feature of all cell membranes is a phospholipid bilayer, about 10 nm thick, arranged with the hydrophilic heads on the outside and the lipophilic chains facing inwards. This gives a sandwich effect, with two hydrophilic layers surrounding the central hydrophobic one. Spanning this bilayer or attached to the outer or inner leaflets are glycoproteins, which may act as ion channels, receptors, intermediate messengers (G-proteins) or enzymes. The cell membrane has been described as a 'fluid mosaic' as the positions of individual phosphoglycerides and glycoproteins are by no means fixed (Figure 1.1). An exception to this is a specialized membrane area such as the neuromuscular junction, where the array of postsynaptic receptors is found opposite a motor nerve ending.

The general cell membrane structure is modified in certain tissues to allow more specialized functions. Capillary endothelial cells have fenestrae, which are regions of the endothelial cell where the outer and inner membranes are fused together, with no intervening cytosol. These make the endothelium of the capillary relatively permeable; fluid in particular can pass rapidly through the cell by this route. In the case of the renal glomerular endothelium, gaps or clefts exist between cells to allow the passage of larger molecules as part of filtration. Tight junctions exist between endothelial cells of brain blood vessels, forming the blood–brain barrier (BBB), intestinal mucosa and renal tubules. These limit the passage of polar molecules and also prevent the lateral movement of glycoproteins within the cell membrane, which may help to keep specialized glycoproteins at their site of action (e.g. transport glycoproteins on the luminal surface of intestinal mucosa) (Figure 1.2).

Methods of crossing the cell membrane

Passive diffusion

This is the commonest method for crossing the cell membrane. Drug molecules move down a concentration gradient, from an area of high concentration to one of low concentration, and the process requires no energy to proceed. Many drugs are weak acids or weak bases and can exist in either the unionized or ionized form, depending on the pH. The unionized form of a drug is lipid-soluble and diffuses easily by dissolution in the lipid bilayer. Thus the rate at which transfer occurs depends on the pK_a of the drug in question. Factors influencing the rate of diffusion are discussed below.



Figure 1.1 Representation of the cell membrane structure. The integral proteins embedded in this phospholipid bilayer are G-protein, G-protein-coupled receptors, transport proteins and ligand-gated ion channels. Additionally, enzymes or voltage-gated ion channels may also be present.



Figure 1.2 Modifications of the general cell membrane structure.

In addition, there are specialized **ion channels** in the membrane that allow intermittent passive movement of selected ions down a concentration gradient. When opened, ion channels allow rapid ion flux for a short time (a few milliseconds) down relatively large concentration and electrical gradients, which makes them suitable to propagate either ligand- or voltage-gated action potentials in nerve and muscle membranes.

The acetylcholine (ACh) receptor has five subunits (pentameric) arranged to form a central ion channel that spans the membrane (Figure 1.3). Of the five subunits, two (the α subunits) are identical. The receptor requires the binding of two ACh molecules to open the ion channel, allowing ions to pass at about 10^7 s^{-1}. If a threshold flux is achieved, depolarization occurs, which is responsible for impulse transmission. The ACh receptor demonstrates selectivity for small cations, but it is by no means specific for Na^+. The $GABA_A$ receptor is also a pentameric, ligand-gated channel, but selective for anions, especially the chloride anion. The NMDA (N-methyl D-aspartate) receptor belongs to a different family of ion channels and is a dimer; it favours calcium as the cation mediating membrane depolarization.



Figure 1.3 The acetylcholine (ACh) receptor has five subunits and spans the cell membrane. ACh binds to the α subunits, causing a conformational change and allowing the passage of small cations through its central ion channel. The ε subunit replaces the fetal-type γ subunit after birth once the neuromuscular junction reaches maturity.

Ion channels may have their permeability altered by endogenous compounds or by drugs. Local anaesthetics bind to the internal surface of the fast Na^+ ion channel and prevent the conformational change required for activation, while non-depolarizing muscle relaxants prevent receptor activation by competitively inhibiting the binding of ACh to its receptor site.

Facilitated diffusion

Facilitated diffusion refers to the process where molecules combine with membrane-bound carrier proteins to cross the membrane. The rate of diffusion of the molecule–protein complex is still down a concentration gradient but is faster than would be expected by diffusion alone. An example of this process is the absorption of glucose, a very polar molecule, which would be relatively slow if it occurred by diffusion alone. There are several transport proteins responsible for facilitated glucose diffusion; they belong to the solute carrier (SLC) family 2. The SLC proteins belonging to family 6 are responsible for transport of neurotransmitters across the synaptic membrane. These are specific for different neurotransmitters: SLC6A3 for dopamine, SLC6A4 for serotonin and SLC6A5 for noradrenaline. They are the targets for certain antidepressants; serotonin-selective re-uptake inhibitors (SSRIs) inhibit SLC6A4.

Active transport

Active transport is an energy-requiring process. The molecule is transported against its concentration gradient by a molecular pump, which requires energy to function. Energy can be supplied either directly to the ion pump, primary active transport, or indirectly by coupling pump-action to an ionic gradient that is actively maintained, secondary active



Figure 1.4 Mechanisms of active transport across the cell membrane.

transport. Active transport is encountered commonly in gut mucosa, the liver, renal tubules and the blood–brain barrier.

Na^+/K^+ ATPase is an example of primary active transport – the energy in the high-energy phosphate bond is lost as the molecule is hydrolysed, with concurrent ion transport against the respective concentration gradients. It is an example of an antiport, as sodium moves in one direction and potassium in the opposite direction. The Na^+/amino acid symport (substances moved in the same direction) in the mucosal cells of the small bowel or on the luminal side of the proximal renal tubule is an example of secondary active transport. Here, amino acids will only cross the mucosal cell membrane when Na^+ is bound to the carrier protein and moves down its concentration gradient (which is generated using Na^+/K^+ ATPase). So, directly and indirectly, Na^+/K^+ ATPase is central to active transport (Figure 1.4).

Primary active transport proteins include the ABC (ATP-binding cassette) family, which are responsible for transport of essential nutrients into and toxins out of cells. An important protein belonging to this family is the multi-drug resistant protein transporter, also known as p-glycoprotein (PGP), which is found in gut mucosa and the blood-brain barrier. Many cytotoxic, antimicrobial and other drugs are substrates for PGP and are unable to penetrate the blood-brain barrier.

The anticoagulant dabigatran is a substrate for PGP and co-administration of PGP inhibitors, such as amiodarone and verapamil, will increase dabigatran bioavailability and therefore the risk of adverse haemorrhagic complications. PGP inducers, such as rifampicin, will reduce dabigatran bioavailability and lead to inadequate anticoagulation.



Figure 1.5 Pinocytosis.

Inhibitors and inducers of PGP are commonly also inhibitors and inducers of CYP3A4 and will interact strongly with drugs that are substrates for both PGP and CYP3A4.

Pinocytosis

Pinocytosis is the process by which an area of the cell membrane invaginates around the (usually large) target molecule and moves it into the cell. The molecule may then be released into the cell or may remain in the vacuole so created, until the reverse process occurs on the opposite side of the cell.

The process is usually used for molecules that are too large to traverse the membrane easily via another mechanism (Figure 1.5).

Factors influencing the rate of diffusion

Molecular size

The rate of passive diffusion is inversely proportional to the square root of molecular size (Graham's law). In general, small molecules will diffuse much more readily than large ones. The molecular weights of anaesthetic agents are relatively small and anaesthetic agents diffuse rapidly through lipid membranes to exert their effects.

Concentration gradient

Fick's law states that the rate of transfer across a membrane is proportional to the concentration gradient across the membrane. Thus increasing the plasma concentration of the unbound fraction of drug will increase its rate of transfer across the membrane and will accelerate the onset of its pharmacological effect. This is the basis of Bowman's principle, applied to the onset of action of non-depolarizing muscle relaxants. The less potent the drug, the more required to exert an effect – but this increases the concentration gradient between plasma and active site, so the onset of action is faster.

Ionization

The lipophilic nature of the cell membrane only permits the passage of the uncharged fraction of any drug. The degree to which a drug is ionized in a solution depends on the

molecular structure of the drug and the pH of the solution in which it is dissolved and is given by the Henderson–Hasselbalch equation.

The pK_a is the pH at which 50% of the drug molecules are ionized – thus the concentrations of ionized and unionized portions are equal. The value for pK_a depends on the molecular structure of the drug and is independent of whether it is acidic or basic.

The Henderson–Hasselbalch equation is most simply expressed as:

$$\mathrm{pH} = \mathrm{pK}_a + \log\left\{\frac{[\text{proton acceptor}]}{[\text{proton donor}]}\right\}.$$

Hence, for an acid (XH), the relationship between the ionized and unionized forms is given by:

$$\mathrm{pH} = \mathrm{pK}_a + \log\left\{\frac{[\mathrm{X}^-1]}{[\mathrm{XH}]}\right\},$$

with X^- being the ionized form of an acid.

For a base (X), the corresponding form of the equation is:

$$\mathrm{pH} = \mathrm{pK}_a + \log\left\{\frac{[\mathrm{X}]}{[\mathrm{XH}^+]}\right\},$$

with XH^+ being the ionized form of a base.

Using the terms 'proton donor' and 'proton acceptor' instead of 'acid' or 'base' in the equation avoids confusion and the degree of ionization of a molecule may be readily established if its pK_a and the ambient pH are known. At a pH below their pK_a weak acids will be more unionized; at a pH above their pK_a they will be more ionized. The reverse is true for weak bases, which are more ionized at a pH below their pK_a and more unionized at a pH above their pK_a.

Bupivacaine is a weak base with a tertiary amine group in the piperidine ring. The nitrogen atom of this amine group is a proton acceptor and can become ionized, depending on pH. With a pK_a of 8.1, it is 83% ionized at physiological pH.

Aspirin is an acid with a pK_a of 3.0. It is almost wholly ionized at physiological pH, although in the highly acidic environment of the stomach it is essentially unionized, which therefore increases its rate of absorption. However, because of the limited surface area within the stomach more is absorbed in the small bowel.

Lipid solubility

The lipid solubility of a drug reflects its ability to pass through the cell membrane; this property is independent of the pK_a of the drug as lipid solubility is quoted for the

unionized form only. However, high lipid solubility alone does not necessarily result in a rapid onset of action. Alfentanil is nearly seven times less lipid-soluble than fentanyl, yet it has a more rapid onset of action. This is a result of several factors. First, alfentanil is less potent and has a smaller distribution volume and therefore initially a greater concentration gradient exists between effect site and plasma. Second, both fentanyl and alfentanil are weak bases and alfentanil has a lower pK_a than fentanyl (alfentanil = 6.5; fentanyl = 8.4), so that at physiological pH a much greater fraction of alfentanil is unionized and available to cross membranes.

Lipid solubility affects the rate of absorption from the site of administration. Fentanyl is suitable for transdermal application as its high lipid solubility results in effective transfer across the skin. Intrathecal diamorphine readily dissolves into, and fixes to, the local lipid tissues, whereas the less lipid-soluble morphine remains in the cerebrospinal fluid longer, and is therefore liable to spread cranially, with an increased risk of respiratory depression.

Protein binding

Only the unbound fraction of drug in plasma is free to cross the cell membrane; drugs vary greatly in the degree of plasma protein binding. In practice, the extent of this binding is of importance only if the drug is highly protein-bound (more than 90%). In these cases, small changes in the bound fraction produce large changes in the amount of unbound drug. In general, this increases the rate at which drug is metabolized, so a new equilibrium is re-established with little change in free drug concentration. For a very small number of highly protein-bound drugs where metabolic pathways are close to saturation (such as phenytoin) this cannot happen and plasma concentration of unbound drug will increase and possibly reach toxic levels.

Both albumin and globulins bind drugs; each has many binding sites, the number and characteristics of which are determined by the pH of plasma. In general, albumin binds neutral or acidic drugs (e.g. barbiturates), and globulins (in particular, α_1 acid glycoprotein) bind basic drugs (e.g. morphine).

Albumin has two important binding sites: the warfarin and diazepam sites. Binding is usually readily reversible, and competition for binding at any one site between different drugs can alter the active unbound fraction of each. Binding is also possible at other sites on the molecule, which may cause a conformational change and indirectly influence binding at the diazepam and warfarin sites.

Although α_1 acid glycoprotein binds basic drugs, other globulins are important in binding individual ions and molecules, particularly the metals. Thus, iron is bound to β_1 globulin and copper to α_2 globulin.

Protein binding is altered in a range of pathological conditions. Inflammation changes the relative proportions of the different proteins and albumin concentration falls in any acute infective or inflammatory process. This effect is independent of any reduction in synthetic capacity resulting from liver impairment and is not due

to protein loss. In conditions of severe hypoalbuminaemia (e.g. in end-stage liver cirrhosis or burns), the proportion of unbound drug increases markedly such that the same dose will have a greatly exaggerated pharmacological effect. The magnitude of these effects may be hard to estimate and drug dose should be titrated against clinical effect.

2 Absorption, distribution, metabolism and excretion

Absorption

Drugs may be given by a variety of routes; the route chosen depends on the desired site of action and the type of drug preparations available. Routes used commonly by the anaesthetist include inhalation, intravenous, oral, intramuscular, rectal, epidural and intrathecal. Other routes, such as transdermal, subcutaneous and sublingual, also can be used. The rate and extent of absorption after a particular route of administration depends on both drug and patient factors.

Not all drugs need to reach the systemic circulation to exert their effects, for example, oral vancomycin used to treat pseudomembranous colitis; antacids also act locally in the stomach. In such cases, systemic absorption may result in unwanted side effects.

Intravenous administration provides a direct, and therefore more reliable, route of systemic drug delivery. No absorption is required, so plasma levels are independent of such factors as gastrointestinal (GI) absorption and adequate skin or muscle perfusion. However, there are disadvantages in using this route. Pharmacological preparations for intravenous therapy are generally more expensive than the corresponding oral medications, and the initially high plasma level achieved with some drugs may cause undesirable side effects. In addition, if central venous access is used, this carries its own risks. Nevertheless, most drugs used in intensive care are given by intravenous infusion this way.

Oral

After oral administration, absorption must take place through the gut mucosa. For drugs without specific transport mechanisms, only unionized drugs pass readily through the lipid membranes of the gut. Because the pH of the GI tract varies along its length, the physicochemical properties of the drug will determine from which part of the GI tract the drug is absorbed.

Acidic drugs (e.g. aspirin) are unionized in the highly acidic medium of the stomach and therefore are absorbed more rapidly than basic drugs. Although weak bases (e.g. propranolol) are ionized in the stomach, they are relatively unionized in the duodenum, so are absorbed from this site. The salts of permanently charged drugs (e.g. vecuronium, glycopyrrolate) remain ionized at all times and are therefore not absorbed from the GI tract.

In practice, even acidic drugs are predominantly absorbed from the small bowel, as the surface area for absorption is so much greater due to the presence of mucosal villi.



Figure 2.1 Bioavailability may be estimated by comparing the areas under the curves.

However, acidic drugs, such as aspirin, have some advantages over basic drugs in that absorption is initially rapid, giving a shorter time of onset from ingestion, and will continue even in the presence of GI tract stasis.

Bioavailability

Bioavailability is generally defined as the fraction of a drug dose reaching the systemic circulation, compared with the same dose given intravenously (i.v.). In general, the oral route has the lowest bioavailability of any route of administration. Bioavailability can be found from the ratio of the areas under the concentration–time curves for an identical bolus dose given both orally and intravenously (Figure 2.1).

Factors influencing bioavailability

- *Pharmaceutical preparation* – the way in which a drug is formulated affects its rate of absorption. If a drug is presented with a small particle size or as a liquid, dispersion is rapid. If the particle size is large, or binding agents prevent drug dissolution in the stomach (e.g. enteric-coated preparations), absorption may be delayed.
- *Physicochemical interactions* – other drugs or food may interact and inactivate or bind the drug in question (e.g. the absorption of tetracyclines is reduced by the concurrent administration of Ca^{2+} such as in milk).
- *Patient factors* – various patient factors affect absorption of a drug. The presence of congenital or acquired malabsorption syndromes, such as coeliac disease or tropical sprue, will affect absorption, and gastric stasis, whether as a result of trauma or drugs, slows the transit time through the gut.
- *Pharmacokinetic interactions and first-pass metabolism* – drugs absorbed from the gut (with the exception of the buccal and rectal mucosa) pass via the portal vein to the liver where they may be subject to first-pass metabolism. Metabolism at either the gut wall (e.g. glyceryl trinitrate (GTN)) or liver will reduce the amount reaching the circulation.



Figure 2.2 First-pass metabolism may occur in the gut wall or in the liver to reduce the amount of drug reaching the circulation.

Therefore, an adequate plasma level may not be achieved orally using a dose similar to that needed intravenously. So, for an orally administered drug, the bioavailable fraction (F_B) is given by:

$$F_B = F_A \times F_G \times F_H$$

Here F_A is the fraction absorbed, F_G the fraction remaining after metabolism in the gut mucosa and F_H the fraction remaining after hepatic metabolism. Therefore, drugs with a high oral bioavailability are stable in the gastrointestinal tract, are well absorbed and undergo minimal first-pass metabolism (Figure 2.2). First-pass metabolism may be increased and oral bioavailability reduced through the induction of hepatic enzymes (e.g. phenobarbital induces hepatic enzymes, reducing the bioavailability of warfarin). Conversely, hepatic enzymes may be inhibited and bioavailability increased (e.g. cimetidine may increase the bioavailability of propranolol).

Extraction ratio

The extraction ratio (ER) is that fraction of drug removed from blood by the liver. ER depends on hepatic blood flow, uptake into the hepatocyte and enzyme metabolic capacity within the hepatocyte. The activity of an enzyme is described by its Michaelis constant, which is the concentration of substrate at which it is working at 50% of its maximum rate. Those enzymes with high metabolic capacity have Michaelis constants very much higher than any substrate concentrations likely to be found clinically; those with low capacity will have Michaelis constants close to clinically relevant concentrations. Drugs fall into three distinct groups:

Drugs for which the hepatocyte has rapid uptake and a high metabolic capacity, for example, propofol and lidocaine. Free drug is rapidly removed from plasma, bound drug is released to maintain equilibrium and a concentration gradient is maintained between plasma and hepatocyte because drug is metabolized very quickly. Because protein binding has rapid equilibration, the total amount of drug metabolized will be independent of protein binding but highly dependent on liver blood flow.

Drugs that have low metabolic capacity and high level of protein binding (>90%). This group includes phenytoin and diazepam. Their ER is limited by the metabolic capacity of the hepatocyte and not by blood flow. If protein binding is altered (e.g. by competition) then the free concentration of drug increases significantly. This initially increases uptake into the hepatocyte and rate of metabolism and plasma levels of free drug do not change significantly. However, if the intracellular concentration exceeds maximum metabolic capacity (saturates the enzyme) drug levels within the cell remain high, so reducing uptake (reduced concentration gradient) and ER. Those drugs with a narrow therapeutic index may then show significant toxic effects; hence the need for regular checks on plasma concentration, particularly when other medication is altered. Therefore for this group of drugs extraction is influenced by changes in protein binding more than by changes in hepatic blood flow.

Drugs that have low metabolic capacity and low level of protein binding. The total amount of drug metabolized for this group of drugs is unaffected by either by hepatic blood flow or by changes in protein binding.

Sublingual

The sublingual, nasal and buccal routes have two advantages – they are rapid in onset and, by avoiding the portal tract, have a higher bioavailability. This is advantageous for drugs where a rapid effect is essential, for example, GTN spray for angina or sublingual nifedipine for the relatively rapid control of high blood pressure.

Rectal

The rectal route can be used to avoid first-pass metabolism, and may be considered if the oral route is not available. Drugs may be given rectally for their local (e.g. steroids for inflammatory bowel disease), as well as their systemic effects (e.g. diclofenac suppositories for analgesia). There is little evidence that the rectal route is more efficacious than the oral route; it provides a relatively small surface area, and absorption may be slow or incomplete.

Intramuscular

The intramuscular (i.m.) route avoids the problems associated with oral administration and the bioavailable fraction approaches 1.0. The speed of onset is generally more rapid compared with the oral route, and for some drugs approaches that for the intravenous route.

The rate of absorption depends on local perfusion at the site of i.m. injection. Injection at a poorly perfused site may result in delayed absorption and for this reason the well-perfused muscles deltoid, quadriceps or gluteus are preferred. If muscle perfusion is poor as a result of systemic hypotension or local vasoconstriction then an intramuscular injection will not be absorbed until muscle perfusion is restored. Delayed absorption will have two consequences. First, the drug will not be effective within the expected time, which may lead to further doses being given. Second, if perfusion is then restored, plasma levels may suddenly rise into the toxic range. For these reasons, the intravenous route is preferred if there is any doubt as to the adequacy of perfusion.

Not all drugs can be given i.m., for example, phenytoin. Intramuscular injections may be painful (e.g. cyclizine) and may cause a local abscess or haematoma, so should be avoided in the coagulopathic patient. There is also the risk of inadvertent intravenous injection of drug intended for the intramuscular route.

Subcutaneous

Certain drugs are well absorbed from the subcutaneous tissues and this is the favoured route for low-dose heparin therapy. A further indication for this route is where patient compliance is a problem and depot preparations may be useful. Anti-psychotic medication and some contraceptive formulations have been used in this way. Co-preparation of insulin with zinc or protamine can produce a slow absorption profile lasting several hours after subcutaneous administration.

As with the intramuscular route, the kinetics of absorption is dependent on local and regional blood flow, and may be markedly reduced in shock. Again, this has the dual effect of rendering the (non-absorbed) drug initially ineffective, and then subjecting the patient to a bolus once the perfusion is restored.

Transdermal

Drugs may be applied to the skin either for local topical effect, such as steroids, but also may be used to avoid first-pass metabolism and improve bioavailability. Thus, fentanyl and nitrates may be given transdermally for their systemic effects. Factors favouring transdermal absorption are high lipid solubility and a good regional blood supply to the site of application (therefore, the thorax and abdomen are preferred to limbs). Special transdermal formulations (patches) are used to ensure slow, constant release of drug for absorption and provide a smoother pharmacokinetic profile. Only small amounts of drug are released at a time, so potent drugs are better suited to this route of administration if systemic effects are required.

Local anaesthetics may be applied topically to anaesthetize the skin before venepuncture, skin grafts or minor surgical procedures. The two most common preparations are topical EMLA and topical amethocaine. The first is a eutectic mixture (each agent lowers the boiling point of the other forming a gel-phase) of lidocaine and prilocaine. Amethocaine is an ester-linked local anaesthetic, which may cause mild, local histamine

release producing local vasodilatation, in contrast to the vasoconstriction seen with eutectic mixture of local anaesthetic (EMLA). Venodilatation may be useful when anaesthetizing the skin prior to venepuncture.

Inhalation

Inhaled drugs may be intended for local or systemic action. The particle size and method of administration are significant factors in determining whether a drug reaches the alveolus and, therefore, the systemic circulation, or whether it only reaches the upper airways. Droplets of less than 1 micron diameter (which may be generated by an ultrasonic nebulizer) can reach the alveolus and hence the systemic circulation. However, a larger droplet or particle size reaches only airway mucosa from the larynx to the bronchioles (and often is swallowed from the pharynx) so that virtually none reaches the alveolus.

Local site of action

The bronchial airways are the intended site of action for inhaled or nebulized bronchodilators. However, drugs given for a local or topical effect may be absorbed resulting in unwanted systemic effects. Chronic use of inhaled steroids may lead to Cushingoid side effects, whereas high doses of inhaled β_2-agonists (e.g. salbutamol) may lead to tachycardia and hypokalaemia. Nebulized adrenaline, used for upper airway oedema causing stridor, may be absorbed and can lead to significant tachycardia, arrhythmias and hypertension, although catecholamines are readily metabolized by lung tissue. Similarly, sufficient quantities of topical lidocaine applied prior to fibreoptic intubation may be absorbed and cause systemic toxicity.

Inhaled nitric oxide reaches the alveolus and dilates the pulmonary vasculature. It is absorbed into the pulmonary circulation but does not produce unwanted systemic effects as it has a short half-life, as a result of binding to haemoglobin.

Systemic site of action

The large surface area of the lungs (70 m^2 in an adult) available for absorption can lead to a rapid increase in systemic concentration and hence rapid onset of action at distant effect sites. Volatile anaesthetic agents are given by the inhalation route with their ultimate site of action the central nervous system.

The kinetics of the inhaled anaesthetics are covered in greater detail in Chapter 9.

Epidural

The epidural route is used to provide regional analgesia and anaesthesia. Epidural local anaesthetics, opioids, ketamine and clonidine have all been used to treat acute pain, whereas steroids are used for diagnostic and therapeutic purposes in patients with chronic pain. Drug may be given as a single-shot bolus or through a catheter placed in the epidural space as a series of boluses or by infusion.

The speed of onset of block is determined by the proportion of unionized drug available to penetrate the cell membrane. Local anaesthetics are bases with pK_as greater than 7.4 so are predominantly ionized at physiological pH (see Chapter 1). Local anaesthetics with a low pK_a, such as lidocaine, will be less ionized and onset of the block will be faster than for bupivacaine, which has a higher pK_a. Thus lidocaine rather than bupivacaine is often used to 'top up' an existing epidural before surgery. Adding sodium bicarbonate to a local anaesthetic solution increases pH and the unionized fraction, further reducing the onset time. Duration of block depends on tissue binding; bupivacaine has a longer duration of action than lidocaine. The addition of a vasoconstrictor, such as adrenaline or felypressin, will also increase the duration of the block by reducing loss of local anaesthetic from the epidural space.

Significant amounts of drug may be absorbed from the epidural space into the systemic circulation especially during infusions. Local anaesthetics and opioids are both commonly administered via the epidural route and carry significant morbidity when toxic systemic levels are reached.

Intrathecal

Compared with the epidural route, the amount of drug required when given intrathecally is very small; little reaches the systemic circulation and this rarely causes unwanted systemic effects. The extent of spread of a subarachnoid block with local anaesthetic depends on volume and type of solution used. Appropriate positioning of the patient when using hyperbaric solutions, such as with 'heavy' bupivacaine, can limit the spread of block.

Distribution

Drug distribution depends on factors that influence the passage of drug across the cell membrane (see Chapter 1) and on regional blood flow. Physicochemical factors include: molecular size, lipid solubility, degree of ionization and protein binding. Drugs fall into one of three general groups:

- *Those confined to the plasma* – certain drugs (e.g. dextran 70) are too large to cross the vascular endothelium. Other drugs (e.g. warfarin) may be so intensely protein-bound that the unbound fraction is tiny, so that the amount available to leave the circulation is immeasurably small.
- *Those with limited distribution* – the non-depolarizing muscle relaxants are polar, poorly lipid-soluble and bulky. Therefore, their distribution is limited to tissues supplied by capillaries with fenestrae (i.e. muscle) that allow their movement out of the plasma. They cannot cross cell membranes but work extracellularly.
- *Those with extensive distribution* – these drugs are often highly lipid-soluble. Providing their molecular size is relatively small, the extent of plasma protein binding does not restrict their distribution due to the weak nature of such interactions. Other drugs are sequestered by tissues (amiodarone by fat; iodine by the thyroid; tetracyclines by bone), which effectively removes them from the circulation.

Those drugs that are not confined to the plasma are initially distributed to tissues with the highest blood flow (brain, lung, kidney, thyroid, adrenal) then to tissues with a moderate blood flow (muscle), and finally to tissues with a very low blood flow (fat). These three groups of tissues provide a useful model when explaining how plasma levels decline after drug administration.

Blood–brain barrier

The blood–brain barrier (BBB) is an anatomical and functional barrier between the circulation and the central nervous system (see Chapter 1).

Active transport and facilitated diffusion are the predominant methods of molecular transfer, which in health is tightly controlled. Glucose and hormones, such as insulin, cross by active carrier transport, while only lipid-soluble, low molecular weight drugs can cross by simple diffusion. Thus inhaled and intravenous anaesthetics can cross readily whereas the larger, polar muscle relaxants cannot and have no central effect. Similarly, glycopyrrolate has a quaternary, charged nitrogen and does not cross the BBB readily. This is in contrast to atropine, a tertiary amine, which may cause centrally mediated effects such as confusion or paradoxical bradycardia. The presence of ABC transport proteins protect the brain from toxins as well as certain antibiotics and cytotoxics (see Chapter 1).

As well as providing an anatomical barrier, the BBB contains enzymes such as monoamine oxidase. Therefore, monoamines are converted to non-active metabolites by passing through the BBB. Physical disruption of the BBB may lead to central neurotransmitters being released into the systemic circulation and may help explain the marked circulatory disturbance seen with head injury and subarachnoid haemorrhage.

In the healthy subject penicillin penetrates the BBB poorly. However, in meningitis, the nature of the BBB alters as it becomes inflamed, and permeability to penicillin (and other drugs) increases, so allowing therapeutic access.

Drug distribution to the fetus

The placental membrane that separates fetal and maternal blood is initially derived from adjacent placental syncytiotrophoblast and fetal capillary membranes, which subsequently fuse to form a single membrane. Being phospholipid in nature, the placental membrane is more readily crossed by lipid-soluble than polar molecules. It is much less selective than the BBB and even molecules with only moderate lipid solubility appear to cross with relative ease and significant quantities may appear in cord (fetal) blood. Placental blood flow and the free drug concentration gradient between maternal and fetal blood determine the rate at which drug equilibration takes place. The pH of fetal blood is lower than that of the mother and fetal plasma protein binding may therefore differ. High protein binding in the fetus increases drug transfer across the placenta since fetal free drug levels are low. In contrast, high protein binding in the mother reduces the rate of drug transfer since maternal free drug levels are low. The fetus also may metabolize some drugs; the rate of metabolism increases as the fetus matures.

The effects of maternal pharmacology on the fetus may be divided into those effects that occur in pregnancy, especially the early first trimester when organogenesis occurs, and at birth.

Drugs during pregnancy

The safety of any drug in pregnancy must be evaluated, but interspecies variation is great and animal models may not exclude the possibility of significant human teratogenicity. In addition, teratogenic effects may not be apparent for some years; stilboestrol taken during pregnancy predisposes female offspring to ovarian cancer at puberty. Wherever possible drug therapy should be avoided throughout pregnancy; if treatment is essential drugs with a long history of safety should be selected.

There are conditions, however, in which the risk of not taking medication outweighs the theoretical or actual risk of teratogenicity. Thus, in epilepsy the risk of hypoxic damage to the fetus secondary to fitting warrants the continuation of anti-epileptic medication during pregnancy. Similarly, the presence of an artificial heart valve mandates the continuation of anticoagulation despite the attendant risks.

Drugs at the time of birth

The newborn may have anaesthetic or analgesic drugs in their circulation depending on the type of analgesia for labour and whether delivery was operative. Drugs with a low molecular weight that are lipid-soluble will be present in higher concentrations than large polar molecules.

Bupivacaine is the local anaesthetic most commonly used for epidural analgesia. It crosses the placenta less readily than does lidocaine as its higher pK_a makes it more ionized than lidocaine at physiological pH. However, the fetus is relatively acidic with respect to the mother, and if the fetal pH is reduced further due to placental insufficiency, the phenomenon of ion trapping may become significant. The fraction of ionized bupivacaine within the fetus increases as the fetal pH falls, its charge preventing it from leaving the fetal circulation, so that levels rise toward toxicity at birth.

Pethidine is commonly used for analgesia during labour. The high lipid solubility of pethidine enables significant amounts to cross the placenta and reach the fetus. It is metabolized to norpethidine, which is less lipid-soluble and can accumulate in the fetus, levels peaking about 4 hours after the initial maternal intramuscular dose. Owing to reduced fetal clearance the half-lives of both pethidine and norpethidine are prolonged up to three times.

Thiopental crosses the placenta rapidly, and experimentally it has been detected in the umbilical vein within 30 seconds of administration to the mother. Serial samples have shown that the peak umbilical artery (and hence fetal) levels occur within 3 minutes of maternal injection. There is no evidence that fetal outcome is affected with an 'injection to delivery' time of up to 20 minutes after injection of a sleep dose of thiopental to the mother.

The non-depolarizing muscle relaxants are large polar molecules and essentially do not cross the placenta. Therefore, the fetal neuromuscular junction is not affected. Only very small amounts of succinylcholine cross the placenta, though again this usually has little effect. However, if the mother has an inherited enzyme deficiency and cannot metabolize succinylcholine, then maternal levels may remain high and a significant degree of transfer may occur. This may be especially significant if the fetus has also inherited the enzyme defect, in which case there may be a degree of depolarizing blockade at the fetal neuromuscular junction.

Metabolism

While metabolism usually reduces the activity of a drug, activity may be designed to increase; a prodrug is defined as a drug that has no inherent activity before metabolism but that is converted by the body to an active moiety. Examples of prodrugs are enalapril (metabolized to enalaprilat), diamorphine (metabolized to 6-monoacylmorphine), and parecoxib (metabolized to valdecoxib). Metabolites also may have equivalent activity to the parent compound, in which case duration of action is not related to plasma levels of the parent drug.

In general, metabolism produces a more polar (water soluble) molecule that can be excreted in the bile or urine – the chief routes of drug excretion. There are two phases of metabolism, I and II.

Phase I (functionalization or non-synthetic)

- Oxidation
- Reduction
- Hydrolysis

Many phase I reactions, particularly oxidative pathways, occur in the liver due to a non-specific mixed-function oxidase system in the endoplasmic reticulum. These enzymes form the cytochrome P450 system, named after the wavelength (in nm) of their maximal absorption of light when the reduced state is combined with carbon monoxide. However, this cytochrome system is not unique to the liver; these enzymes are also found in gut mucosa, lung, brain and kidney. Methoxyflurane is metabolized by CYP2E1 in the kidney, generating a high local concentration of fluoride ions, which was the cause of renal failure seen with this agent (see sevoflurane metabolism, p. 123).

The enzymes of the cytochrome P450 system are classified into families and subfamilies by their degree of shared amino acid sequences – families and subfamilies share 40% and 55% respectively of the amino acid sequence. In addition, the subfamilies are further divided into isoforms. Families are labelled CYP1, CYP2, and so on, the subfamilies CYP1A, CYP1B, and so on, and the isoforms CYP1A1, CYP1A2, and so on. Table 2.1 summarizes isoenzymes of particular importance in the metabolism of drugs relevant to the anaesthetist. Many drugs are metabolized by more than one isozyme (e.g. midazolam by CYP3A4 and CYP3A5). Genetic variants are also found,

Table 2.1 Metabolism of drugs by cytochrome P450 system. CYP2C9, CYP2C19 and CYP2D6 all demonstrate significant genetic polymorphism; other cytochromes also have variants, but these are clinically important. Losartan is a prodrug, as well as clopidogrel, so poor activity of CYP2C9 and CYP2C19 respectively will limit active product availability.

CYP2B6	CYP2C9	CYP2C19	CYP2D6	CYP2E1	CYP3A4	CYP3A5
propofol	propofol parecoxib losartan S-warfarin	losartan diazepam phenytoin omeprazole clopidogrel	codeine flecainide metoprolol	sevoflurane halothane isoflurane paracetamol	diazepam temazepam midazolam fentanyl alfentanil lidocaine vecuronium	diazepam

in particular CYP2D6 and CYP2C9; variants of CYP2D6 are associated with defective metabolism of codeine.

In addition to abnormal alleles, some people have multiple copies of the *CYP2D6* gene – all of which are expressed. As a result, these ultrafast metabolizers convert codeine to morphine very rapidly and experience unpleasant side effects of morphine rather than an effective analgesic effect.

The P450 system is not responsible for all phase I metabolism. The monoamines (adrenaline, noradrenaline, dopamine) are metabolized by the mitochondrial enzyme monoamine oxidase. Individual genetic variation, or the presence of exogenous inhibitors of this breakdown pathway, can result in high levels of monoamines in the circulation, with severe cardiovascular effects. Ethanol is metabolized by the cytoplasmic enzyme alcohol dehydrogenase to acetaldehyde, which is then further oxidized to acetic acid. This enzyme is one that is readily saturated, leading to a rapid increase in plasma ethanol if consumption continues. Esterases are also found in the cytoplasm of a variety of tissues, including liver and muscle, and are responsible for the metabolism of esters, such as etomidate, aspirin, atracurium and remifentanil. The lung also contains an angiotensin-converting enzyme that is responsible for AT1 to AT2 conversion; this enzyme is also able to break down bradykinin.

In addition, some metabolic processes take place in the plasma: cisatracurium breaks down spontaneously in a pH- and temperature-dependent manner – Hofmann degradation – and succinylcholine is hydrolysed by plasma cholinesterase.

Phase II (conjugation or synthetic)

- Glucuronidation (e.g. morphine, propofol)
- Sulfation (e.g. quinol metabolite of propofol)
- Acetylation (e.g. isoniazid, sulfonamides)
- Methylation (e.g. catechols, such as noradrenaline)

Although many drugs are initially metabolized by phase I processes followed by a phase II reaction, some drugs are modified by phase II reactions only. Phase II reactions increase the water solubility of the drug or metabolite to allow excretion into the bile or urine. They occur mainly in the hepatic endoplasmic reticulum but other sites, such as the lung, may also be involved. This is especially true in the case of acetylation, which also occurs in the lung and spleen.

In liver failure, phase I reactions are generally affected before phase II, so drugs with a predominantly phase II metabolism, such as lorazepam, are less affected.

Genetic polymorphism

There are inherited differences in enzyme structure that alter the way drugs are metabolized in the body. The genetic polymorphisms of particular relevance to anaesthesia are those of plasma cholinesterase, those involved in acetylation and the CYP2D6 variants mentioned above.

Succinylcholine is metabolized by hydrolysis in the plasma, a reaction that is catalysed by the relatively non-specific enzyme plasma cholinesterase. Certain individuals have an unusual variant of the enzyme and metabolize succinylcholine much more slowly. Several autosomal recessive genes have been identified, and these may be distinguished by the degree of enzyme inhibition demonstrated in vitro by substances such as fluoride and the local anaesthetic dibucaine. Muscle paralysis due to succinylcholine may be prolonged in individuals with an abnormal form of the enzyme. This is discussed in greater detail in Chapter 11.

Acetylation is a phase II metabolic pathway in the liver. Drugs metabolized by N-acetyltransferase type 2 (NAT2) include hydralazine and isoniazid. There are genetically different isoenzymes of NAT2 that acetylate at a slow or fast rate. The pharmacokinetic and hence pharmacodynamic profile seen with these drugs depends on the acetylator status of the individual.

Enzyme inhibition and induction

Some drugs (Table 2.2) induce the activity of the hepatic microsomal enzymes. The rate of metabolism of the enzyme-inducing drug as well as other drugs is increased and may lead to reduced plasma levels. Other drugs, especially those with an imidazole structure (e.g. cimetidine), inhibit the activity of hepatic microsomal enzymes and may result in increased plasma levels.

Excretion

Elimination refers to the processes of removal of the drug from the plasma and includes distribution and metabolism, while excretion refers to the removal of drug from the body. The chief sites of excretion are in the urine and the bile (and hence the gastrointestinal tract), although traces of drug are also detectable in tears and breast milk. The chief route of excretion of the volatile anaesthetic agents is via the lungs; however, metabolites are

Table 2.2 Effects of various drugs on hepatic microsomal enzymes.

	Inducing	Inhibiting
Antibiotics	rifampicin	metronidazole, isoniazid, chloramphenicol acute use
Alcohol	chronic abuse	
Inhaled anaesthetics	enflurane, halothane	
Barbiturates	phenobarbital, thiopental	
Anticonvulsants	phenytoin, carbamazepine	
Hormones	glucocorticoids	
MAOIs		phenelzine, tranylcypromine
H_2 antagonists		cimetidine
Others	cigarette smoking	amiodarone, grapefruit juice

detectable in urine, and indeed the metabolites of agents such as methoxyflurane may have a significant effect on renal function.

The relative contributions from different routes of excretion depend upon the structure and molecular weight of a drug. In general, high molecular weight compounds (>30 000) are not filtered or secreted by the kidney and are therefore preferentially excreted in the bile. A significant fraction of a drug carrying a permanent charge, such as pancuronium, may be excreted unchanged in urine.

Renal excretion

Filtration at the glomerulus

Small, non-protein-bound, poorly lipid-soluble but readily water-soluble drugs are excreted into the glomerular ultrafiltrate. Only free drug present in that fraction of plasma that is filtered is removed at the glomerulus. The remaining plasma will have the same concentration of free drug as that fraction filtered and so there is no change in the extent of plasma protein binding. Thus highly protein-bound drugs are not extensively removed by filtration – but may be excreted by active secretory mechanisms in the tubule.

Secretion at the proximal tubules

There are active energy-requiring processes in the proximal convoluted tubules by which a wide variety of molecules may be secreted into the urine against their concentration gradients. Different carrier systems exist for acidic and basic drugs that are each capacity-limited for their respective drug type (i.e. maximal clearance of one acidic drug will result in a reduced clearance of another acidic drug but not of a basic drug). Drug secretion also may be inhibited, for example, probenecid blocks the secretion of penicillin.

Diffusion at the distal tubules

At the distal tubule, passive diffusion may occur down the concentration gradient. Acidic drugs are preferentially excreted in an alkaline urine as this increases the fraction present

in the ionized form, which cannot be reabsorbed. Conversely, basic drugs are preferentially excreted in acidic urine where they are trapped as cations.

Biliary excretion

High molecular weight compounds, such as the steroid-based muscle relaxants, are excreted in bile. Secretion from the hepatocyte into the biliary canaliculus takes place against a concentration gradient, and is therefore active and energy-requiring, and subject to inhibition and competition for transport. Certain drugs are excreted unchanged in bile (e.g. rifampicin), while others are excreted after conjugation (e.g. morphine metabolites are excreted as glucuronides).

Enterohepatic circulation

Drugs excreted in the bile such as glucuronide conjugates may be hydrolysed in the small bowel by glucuronidase secreted by bacteria. Lipid-soluble, active drugs may result and be reabsorbed, passing into the portal circulation to the liver where the extracted fraction is reconjugated and re-excreted in the bile, and the rest passes into the systemic circulation. This process may continue many times. Failure of the oral contraceptive pill while taking broad-spectrum antibiotics has been blamed on a reduced intestinal bacterial flora causing a reduced enterohepatic circulation of oestrogen and progesterone.

Effect of disease

Renal disease

In the presence of renal disease, those drugs that are normally excreted via the renal tract may accumulate. This effect will vary according to the degree to which the drug is dependent upon renal excretion – in the case of a drug whose clearance is entirely renal a single dose may have a very prolonged effect. This was true of gallamine, a non-depolarizing muscle relaxant, which, if given in the context of renal failure, required dialysis or haemofiltration to reduce the plasma level and hence reverse the pharmacological effect.

If it is essential to give a drug that is highly dependent on renal excretion in the presence of renal impairment, a reduction in dose must be made. If the apparent volume of distribution remains the same, the loading dose also remains the same, but repeated doses may need to be reduced and dosing interval increased. However, due to fluid retention the volume of distribution is often increased in renal failure, so loading doses may be higher than in health.

Knowledge of a patient's creatinine clearance is very helpful in estimating the dose reduction required for a given degree of renal impairment. As an approximation, the dose, D, required in renal failure is given by:

$$D = \text{Usual dose} \times (\text{impaired clearance}/\text{normal clearance}).$$

Tables contained in the *British National Formulary* give an indication of the appropriate reductions in mild, moderate and severe renal impairment.

Liver disease

Hepatic impairment alters many aspects of the pharmacokinetic profile of a drug. Protein synthesis is decreased (hence decreased plasma protein levels and reduced protein binding). Both phase I and II reactions are affected, and thus the metabolism of drugs is reduced. The presence of ascites increases the volume of distribution and the presence of portocaval shunts increases bioavailability by reducing hepatic clearance of drugs.

There is no analogous measure of hepatic function compared with creatinine clearance for renal function. Liver function tests in common clinical use may be divided into those that measure the synthetic function of the liver – the international normalized ratio (INR) or prothrombin time and albumin – and those that measure inflammatory damage of the hepatocyte. It is possible to have a markedly inflamed liver with high transaminase levels, with retention of reasonable synthetic function. In illness, the profile of protein synthesis shifts toward acute phase proteins; albumin is not an acute phase protein so levels are reduced in any acute illness.

Patients with severe liver failure may suffer hepatic encephalopathy as a result of a failure to clear ammonia and other molecules. These patients are very susceptible to the effects of benzodiazepines and opioids, which should therefore be avoided if possible. For patients requiring strong analgesia in the peri-operative period a coexisting coagulopathy will often rule out a regional technique, leaving few other analgesic options other than careful intravenous titration of opioid analgesics, accepting the risk of precipitating encephalopathy.

The extremes of age

Neonate and infant

In the newborn and young, the pharmacokinetic profiles of drugs are different for a number of reasons. These are due to qualitative, as well as quantitative, differences in the neonatal anatomy and physiology.

Fluid compartments

The volume and nature of the pharmacokinetic compartments is different, with the newborn being relatively overhydrated and losing volume through diuresis in the hours and days after birth. As well as the absolute proportion of water being higher, the relative amount in the extracellular compartment is increased. The relative sizes of the organs and regional blood flows are also different from the adult; the neonatal liver is relatively larger than that of an adult although its metabolizing capacity is lower and may not be as efficient.

Distribution

Plasma protein levels and binding are less than in the adult. In addition, the pH of neonatal blood tends to be lower, which alters the relative proportions of ionized and unionized drug. Thus, both the composition and acid-base value of the blood affect plasma protein binding.

Metabolism and excretion

While the neonate is born with several of the enzyme systems functioning at adult levels, the majority of enzymes do not reach maturity for a number of months. Plasma levels of cholinesterase are reduced, and in the liver the activity of the cytochrome P450 family of enzymes is markedly reduced. Newborns have a reduced rate of excretion via the renal tract. The creatinine clearance is less than 10% of the adult rate per unit body weight, with nephron numbers and function not reaching maturity for some months after birth.

Though the implications of many of these differences may be predicted, the precise doses of drugs used in the newborn has largely been determined clinically. Preferred drugs should be those that have been used safely for a number of years, and in which the necessary dose adjustments have been derived empirically. In addition, there is wide variation between individuals of the same post-conceptual age.

Elderly

A number of factors contribute to pharmacokinetic differences observed in the elderly. The elderly have a relative reduction in muscle mass, with a consequent increase in the proportion of fat, altering volume of distribution. This loss of muscle mass is of great importance in determining the sensitivity of the elderly to remifentanil, which is significantly metabolized by muscle esterases. There is a reduction in the activity of hepatic enzymes with increasing age, leading to a relative decrease in hepatic drug clearance. Creatinine clearance diminishes steadily with age, reflecting reduced renal function.

As well as physiological changes with increasing age, the elderly are more likely to have multiple co-existing diseases. The implications of this are two-fold. First, the disease processes may directly alter drug pharmacokinetics and second, polypharmacy may produce drug interactions that alter both pharmacokinetics and pharmacodynamic response.

3 Drug action

Mechanisms of drug action

Drugs may act in a number of ways to exert their effect. These range from relatively simple non-specific actions that depend on the physicochemical properties of a drug to highly specific and stereoselective actions on proteins in the body, namely enzymes, voltage-gated ion channels and receptors.

Actions dependent on chemical properties

The antacids exert their effect by neutralizing gastric acid. The chelating agents are used to reduce the concentration of certain metallic ions within the body. Dicobalt edetate chelates cyanide ions and may be used in cyanide poisoning or following a potentially toxic dose of sodium nitroprusside. The reversal agent γ-cyclodextrin (sugammadex) selectively chelates rocuronium and reversal is possible from deeper levels of block than can be effected with the anticholinesterases.

Enzymes

Enzymes are biological catalysts, and most drugs that interact with enzymes are inhibitors. The results are twofold: the concentration of the substrate normally metabolized by the enzyme is increased and that of the product(s) of the reaction is decreased. Enzyme inhibition may be competitive (edrophonium for anticholinesterase), non-competitive or irreversible (aspirin for cyclo-oxygenase and omeprazole for the Na^+/H^+ ATPase). Angiotensin-converting enzyme (ACE) inhibitors such as ramipril prevent the conversion of angiotensin I to II and bradykinin to various inactive fragments. Although reduced levels of angiotensin II are responsible for the therapeutic effects when used in hypertension and heart failure, raised levels of bradykinin may cause an intractable cough.

Voltage-gated ion channels

Voltage-gated ion channels are involved in conduction of electrical impulses associated with excitable tissues in muscle and nerve. Several groups of drugs have specific blocking actions at these ion channels. Local anaesthetics act by inhibiting Na^+ channels in nerve membrane, several anticonvulsants block similar channels in the brain, calcium channel blocking agents act on vascular smooth muscle ion channels and anti-arrhythmic agents block myocardial ion channels. These actions are described in the relevant chapters in Sections II and III.

Receptors

A receptor is a protein, often integral to a membrane, containing a region to which a natural ligand binds specifically to bring about a response. A drug acting at a receptor binds to a recognition site where it may elicit an effect (an agonist), prevent the action of a natural ligand (an inhibitor), or reduce a constitutive effect of a receptor (an inverse agonist). Natural ligands may also bind to more than one receptor and have a different mechanism of action at each (e.g. ionotropic and metabotropic actions of γ-aminobutyric acid (GABA) at $GABA_A$ and $GABA_B$ receptors).

Receptors are generally protein or glycoprotein in nature and may be associated with or span the cell membrane, be present in the membranes of intracellular organelles or be found in the cytosol or nucleus. Those in the membrane are generally for ligands that do not readily penetrate the cell, whereas those within the cell are for lipid-soluble ligands that can diffuse through the cell wall to their site of action, or for intermediary messengers generated within the cell itself.

Receptors may be grouped into three classes depending on their mechanism of action: (1) altered ion permeability; (2) production of intermediate messengers; and (3) regulation of gene transcription (Figure 3.1).

Altered ion permeability: ion channels

Receptors of this type are part of a membrane-spanning complex of protein subunits that have the potential to form a channel through the membrane. When opened, such a channel allows the passage of ions down their concentration and electrical gradients. Here, ligand binding causes a conformational change in the structure of this membrane protein complex, allowing the channel to open and so increasing the permeability of the membrane to certain ions (ionotropic). There are three important ligand-gated ion channel families: the pentameric, the ionotropic glutamate and the ionotropic purinergic receptors.

The pentameric family

The pentameric family of receptors has five membrane-spanning subunits. The best-known example of this type of ion channel receptors is the nicotinic acetylcholine receptor at the neuromuscular junction. It consists of one β, one ε, one δ and two α subunits. Two acetylcholine molecules bind to the α subunits, resulting in a rapid increase in Na^+ flux through the ion channel formed, leading to membrane depolarization.

Another familiar member of this family is the $GABA_A$ receptor, in which GABA is the natural ligand. Conformational changes induced when the agonist binds cause a chloride-selective ion channel to form, leading to membrane hyperpolarization. The benzodiazepines (BDZs) can influence GABA activity at this receptor but augment chloride ion conductance by an allosteric mechanism (see below for explanation).

The $5\text{-}HT_3$ receptor is also a member of this pentameric family; it is the only serotonin receptor to act through ion-channel opening.



Figure 3.1 Mechanism of action of the three groups of receptors.

Ionotropic glutamate

Glutamate is an excitatory neurotransmitter in the central nervous system (CNS) that works through several receptor types, of which NMDA, AMPA and kainate are ligand-gated ion channels. The NMDA receptors are comprised of two subunits, one pore-forming (NR1) and one regulatory that binds the co-activator, glycine (NR2). In vivo, it is thought that the receptors dimerize, forming a complex with four subunits. Each

NR1 subunit has three membrane-spanning helices, two of which are separated by a re-entrant pore-forming loop. NMDA channels are equally permeable to Na^+ and K^+ but have a particularly high permeability to the divalent cation, Ca^{2+}. Ketamine, xenon and nitrous oxide are non-competitive antagonists at these receptors.

Ionotropic purinergic receptors

This family of receptors includes PX1 and PX2. Each has two membrane-spanning helices and no pore-forming loops. They form cationic channels that are equally permeable to Na^+ and K^+ but are also permeable to Ca^{2+}. These purinergic receptors are activated by ATP and are involved in mechanosensation and pain. These are not to be confused with the two G-protein coupled receptor forms of purinergic receptors, which are distinguished by selectivity for adenosine or ATP.

Production of intermediate messengers

There are several membrane-bound systems that transduce a ligand-generated signal presented on one side of the cell membrane into an intracellular signal transmitted by intermediate messengers. The most common is the G-protein coupled receptor system but there are others including the tyrosine kinase and guanylyl cyclase systems.

G-protein coupled receptors (GPCRs) and G-proteins

GPCRs are membrane-bound proteins with a serpentine structure consisting of seven helical regions that traverse the membrane. G-proteins are a group of heterotrimeric (three different subunits, α, β and γ) proteins associated with the inner leaflet of the cell membrane that act as universal transducers involved in bringing about an intracellular change from an extracellular stimulus. The GPCR binds a ligand on its extracellular side and the resultant conformational change increases the likelihood of coupling with a particular type of G-protein resulting in activation of intermediate messengers at the expense of GTP (guanylyl triphosphate) breakdown. This type of receptor interaction is sometimes known as **metabotropic** in contrast with ionotropic for ion-channel forming receptors. As well as transmitting a stimulus across the cell membrane the G-protein system produces signal amplification, whereby a modest stimulus may have a much greater intracellular response. This amplification occurs at two levels: a single activated GPCR can stimulate multiple G-proteins and each G-protein can activate several intermediate messengers.

G-proteins bind GDP and GTP, hence the name 'G-protein'. In the inactive form GDP is bound to the α subunit but on interaction with an activated GPCR GTP replaces GDP, giving a complex of α-GTP-βγ. The α-GTP subunit then dissociates from the βγ dimer and activates or inhibits an effector protein, either an enzyme, such as **adenylyl cyclase** or **phospholipase C** (Figure 3.2) or an ion channel. For example, β-adrenergic agonists activate adenylyl cyclase and opioid receptor agonists, such as morphine, depress transmission of pain signals via inhibition of N-type Ca^{2+} channels through G-protein mechanisms. In some systems, the βγ dimer can also activate intermediary mechanisms.